- The Washington Times - Tuesday, August 15, 2017

Scientists studying the infection of the Herpes virus stumbled upon the potential for a broad-spectrum antiviral solution, that can suppress the common sexually transmitted infection but has the potential to offer relief for a wide range of infections, including the Zika virus.

The study was led by Jesse Arbuckle of the National Institute of Allergy and Infectious Diseases and was published Tuesday in the journal for the American Society for Microbiology.

While conducting mice trials, researchers found that suppression of an enzyme complex related to Herpes Simplex Virus suppressed viral infection, spread and reactivation of the virus.

The World Health Organization estimates that two-thirds of the global population carry the HSV-1, which most commonly is expressed by oral cold sores, and that at least 500 million people are infected with HSV-2, which can be transmitted sexually and results in sores on the genitals in addition to a host of other diseases. If Herpes is contracted by infants, it can lead to neurological damage and even death.

The scientists were researching how when the herpes virus infects a cell, its genomes assemble into special protein structures called nucleosomes, according to a statement by the National Institutes of Health. Reactions inside cells to the virus can either promote or inhibit the spread of the infection. While evaluating the enzyme complex EZH2/1, scientists found that it inhibited the spread of the herpesvirus.

“Scientists studying how one of these complexes (EZH2/1) regulated herpes simplex virus (HSV) infection unexpectedly found that inhibiting EZH2/1 suppressed viral infection,” the statement from NIH read.

They were able to replicate their findings in cultured human cells.

Not only that, they believe inhibiting this enzyme complex can be used to suppress a number of viral infections, including the Zika virus and a wide range of adenoviruses – infections like the common cold, sore throats, bronchitis, diarrhea, fever and more.

Copyright © 2018 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times is switching its third-party commenting system from Disqus to Spot.IM. You will need to either create an account with Spot.im or if you wish to use your Disqus account look under the Conversation for the link "Have a Disqus Account?". Please read our Comment Policy before commenting.

 

Click to Read More

Click to Hide